Regulation of DNA replication and repair
DNA复制和修复的调节
基本信息
- 批准号:7627423
- 负责人:
- 金额:$ 30.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-05-01 至 2009-05-31
- 项目状态:已结题
- 来源:
- 关键词:Antibiotic ResistanceAntibioticsAreaBindingBiochemicalBiological AssayBypassCell CycleClassComplementComplexDNADNA Polymerase IIIDNA Polymerase betaDNA RepairDNA biosynthesisDNA chemical synthesisDNA-Directed DNA PolymeraseDepthDevelopmentE coli replicaseEscherichia coliFailureFamilyGeneticGenome StabilityGenomic InstabilityGoalsHandHoloenzymesHumanImmunoglobulin Somatic HypermutationImmunoglobulinsIn VitroLaboratoriesLeadLifeMalignant NeoplasmsMediatingModelingMutagenesisMutationOrganismPathogenesisPhenotypePlayPolymeraseProcessProteinsReagentRegulationReplication ErrorReplication InitiationResearchRoleSlideStressSurfaceTestingTimeTravelWorkbasechromatin immunoprecipitationgenetic analysishuman diseasein vitro Assaymutantnovelpol genespreventprogramsrepairedresearch study
项目摘要
The long-term goal of this research program is to develop an integrated mechanistic view of how
organisms coordinate the actions of their replication machinery with those of other cellular factors involved in
DNA repair and damage tolerance. Failure to do so leads to a loss of genetic fidelity and contributes to human
disease. Furthermore, inappropriate regulation of Y-family DNA polymerase function is proposed to contribute
to mutations that lead to cancer. Work from our laboratory and others have demonstrated unambiguously that
DNA polymerase processivity clamps (¿ or DnaN sliding clamps) play critically important roles in this complex
process. The proposed research program utilizes an integrated genetic¿biochemical¿physical biochemical
approach, placing particular emphasis on determining how the ¿ clamp helps to coordinate the actions of the
E. coli replicase, DNA polymerase III holoenzyme (Pol III), with the dinB-encoded Pol IV, which acts in
translesion DNA synthesis (TLS), and with the Hda protein, which helps to regulate initiation of DNA replication
by inactivating the DnaA initiator protein. We will utilize in vitro assays to characterize interactions of Pol III and
Pol IV with various mutant ¿ clamp proteins. As part of this work, we will purify heterodimeric clamp proteins
bearing either a single mutation in one subunit, or different mutations in each subunit. Using these mutant
clamps, we will dissect the mechanism by which the ¿ clamp mediates a switch between Pol III and Pol IV to
coordinate high fidelity replication with TLS. We will complement these studies with genetic analyses. We
anticipate that the model(s) for polymerase switching supported by our results will serve as a valuable
paradigm for similar switch mechanisms in other organisms, including humans. In addition, since Y-family Pols
are remarkably well conserved throughout all three branches of life, results from our studies will also contribute
significantly to our understanding of mechanisms underlying mutagenesis under times of stress, thereby
impacting on pathogenesis and antibiotic resistance, as well as mechanisms contributing to immunoglobulin
diversity by error-prone replication during somatic hypermutation. We will also apply the approaches that we
have developed to characterize polymerase switching to Hda protein in order to understand the role of the ¿
clamp in coordinating replication with Hda-dependent regulation of initiation of replication. Failure to properly
regulate initiation leads to over-replication, genome instability, and can be lethal. We will distinguish between
different models for Hda function, and will determine whether Hda and Pol III simultaneously bind to the same
¿ clamp. We will also determine whether Hda acts to limit access of Y-family Pols to the replication fork until
such time as they are required for TLS. Finally, since replication errors contribute significantly to mutagenesis,
and since the coordinate regulation of initiation and elongation of DNA replication is critically important for
genome stability, our findings in these areas may also identify new classes of targets for the development of
novel antibiotics.
该研究计划的长期目标是建立一个综合的机制观点,以了解如何
生物体协调其复制机制的行为与参与复制的其他细胞因子的行为
DNA 修复和损伤耐受性失败会导致遗传保真度的丧失,并对人类做出贡献。
此外,Y 家族 DNA 聚合酶功能的不当调节也可能导致疾病。
我们实验室和其他实验室的工作已经明确地证明了这一点。
DNA 聚合酶持续钳(¿ 或 DnaN 滑动钳)在此复合体中发挥着至关重要的作用
拟议的研究计划利用了综合遗传技术。生物化学??物理生物化学
方法,特别强调确定如何夹子有助于协调动作
大肠杆菌复制酶、DNA 聚合酶 III 全酶 (Pol III),以及 dinB 编码的 Pol IV,其作用于
跨损伤 DNA 合成 (TLS),以及 Hda 蛋白,有助于调节 DNA 复制的起始
通过灭活 DnaA 起始蛋白,我们将利用体外测定来表征 Pol III 和 Pol III 的相互作用。
Pol IV 与各种突变体 ¿作为这项工作的一部分,我们将纯化异二聚体钳蛋白。
使用这些突变体可以在一个亚基中携带单个突变,或者在每个亚基中携带不同的突变。
夹子,我们将剖析 ¿钳位介导 Pol III 和 Pol IV 之间的转换
我们将通过遗传分析来补充这些研究。
预计我们的结果支持的聚合酶转换模型将成为有价值的
包括人类在内的其他生物体中类似开关机制的范例。
令人惊讶的是,它们在生命的所有三个分支中都保存得很好,我们的研究结果也将做出贡献
对我们对压力下诱变机制的理解具有重要意义,从而
对发病机制和抗生素耐药性的影响,以及免疫球蛋白的机制
我们还将应用我们在体细胞超突变过程中容易出错的复制来实现多样性。
已经开发出表征聚合酶转换为 Hda 蛋白的特征,以了解 ¿
钳制复制与 Hda 依赖性复制起始调节的协调失败。
调节启动会导致过度复制、基因组不稳定,并且可能是致命的。我们将区分它们。
Hda 功能的不同模型,并将确定 Hda 和 Pol III 是否同时结合到相同的
¿我们还将确定 Hda 是否会限制 Y 家族 Pols 访问复制叉,直到
最后,由于复制错误会显着导致突变,
并且由于 DNA 复制起始和延伸的协调调节对于 DNA 复制至关重要
基因组稳定性,我们在这些领域的发现也可能确定用于开发的新靶标
新型抗生素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK D. SUTTON其他文献
MARK D. SUTTON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK D. SUTTON', 18)}}的其他基金
Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa
对抗高突变碳青霉烯类耐药铜绿假单胞菌的新型联合疗法
- 批准号:
10626966 - 财政年份:2022
- 资助金额:
$ 30.84万 - 项目类别:
Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa
对抗高突变碳青霉烯类耐药铜绿假单胞菌的新型联合疗法
- 批准号:
10522530 - 财政年份:2022
- 资助金额:
$ 30.84万 - 项目类别:
Purification and Initial Biochemical Analysis of the P. aeruginosa ImuABC Error-Prone DNA Polymerase
铜绿假单胞菌 ImuABC 易错 DNA 聚合酶的纯化和初步生化分析
- 批准号:
10094185 - 财政年份:2020
- 资助金额:
$ 30.84万 - 项目类别:
Purification and Initial Biochemical Analysis of the P. aeruginosa ImuABC Error-Prone DNA Polymerase
铜绿假单胞菌 ImuABC 易错 DNA 聚合酶的纯化和初步生化分析
- 批准号:
9891550 - 财政年份:2020
- 资助金额:
$ 30.84万 - 项目类别:
Coordination of DNA replication, repair, and translesion DNA synthesis
DNA 复制、修复和跨损伤 DNA 合成的协调
- 批准号:
8630539 - 财政年份:2003
- 资助金额:
$ 30.84万 - 项目类别:
Coordination of DNA replication, repair, and translesion DNA synthesis
DNA 复制、修复和跨损伤 DNA 合成的协调
- 批准号:
8744275 - 财政年份:2003
- 资助金额:
$ 30.84万 - 项目类别:
相似国自然基金
跨区域视角下人类活动对农业抗生素排放的驱动机制及优化调控
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于污水流行病学的全国重点城市医疗用抗生素使用水平研究
- 批准号:41877508
- 批准年份:2018
- 资助金额:61.0 万元
- 项目类别:面上项目
典型城市区域水体中抗生素类药物迁移转化及其生态毒性研究
- 批准号:41773121
- 批准年份:2017
- 资助金额:68.0 万元
- 项目类别:面上项目
氟喹诺酮类抗生素受体蛋白的制备、分析方法的建立及区域环境水体的生态风险评估
- 批准号:41601552
- 批准年份:2016
- 资助金额:19.0 万元
- 项目类别:青年科学基金项目
水产养殖环境中ISCR元件介导的抗生素抗性基因水平传播及生态风险
- 批准号:31200398
- 批准年份:2012
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Expanding the small molecule toolbox through novel applications of fluorinated alkenes
通过氟化烯烃的新颖应用扩展小分子工具箱
- 批准号:
10714822 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
Prognostic modeling of pediatric tracheostomy-associated respiratory tract infections
儿童气管切开相关呼吸道感染的预后模型
- 批准号:
10661889 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
A Novel Sublingual Vaccine to Prevent Neisseria Gonorrhoeae Infection
预防淋病奈瑟菌感染的新型舌下疫苗
- 批准号:
10699065 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
STI NG Plus, a Swab to Answer Molecular Panel Test for Point of Care Diagnosis and Treatment Recommendation
STI NG Plus,一种拭子,可回答用于护理点诊断和治疗建议的分子面板测试
- 批准号:
10603834 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
- 批准号:
10645989 - 财政年份:2023
- 资助金额:
$ 30.84万 - 项目类别: